By ThinkSabio #ThinkSabio Latest News
Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177
Clinical Remission: Achieved in 33% of PL8177-treated patients versus 0% on placebo after eight weeks of treatment.
Clinical Response Demonstrated in 78% of PL8177-treated patients versus 33% on placebo after eight wks of treatment (p<0.005)